Abstract:Natriuretic peptides (NPs) may work as neuromodulators through their associated receptors [NP receptors (NPRs)]. By immunocytochemistry, we showed that NPR-A and NPR-B were expressed abundantly on both ON-type and OFF-type bipolar cells (BCs) in rat retina, including the dendrites, somata, and axon terminals. Whole-cell recordings made from isolated ON-type BCs further showed that brain natriuretic peptide (BNP) suppressed GABA(A) receptor-, but not GABA(C) receptor-, mediated currents of the BCs, which was blocked by the NPR-A antagonist anantin. The NPR-C agonist c-ANF [des(Gln(18), Ser(19), Gln(20), Leu(21), Gly(22))ANF(4-23)-NH2] did not suppress GABA(A) currents. The BNP effect on GABA(A) currents was abolished with preincubation with the pGC-A/B antagonist HS-142-1 but mimicked by application of 8-bromoguanosine-3',5'-cyclomonophosphate. These results suggest that elevated levels of intracellular cGMP caused by activation of NPR-A may mediate the BNP effect. Internal infusion of the cGMP-dependent protein kinase G (PKG) inhibitor KT5823 essentially blocked the BNP-induced reduction of GABA(A) currents. Moreover, calcium imaging showed that BNP caused a significant elevation of intracellular calcium that could be caused by increased calcium release from intracellular stores by PKG. The BNP effect was blocked by the ryanodine receptor modulators caffeine, ryanodine, and ruthenium red but not by the IP3 receptor antagonists heparin and xestospongin-C. Furthermore, the BNP effect was abolished after application of the blocker of endoplasmic reticulum Ca2+-ATPase thapsigargin and greatly reduced by the calmodulin inhibitors W-7 and calmidazolium. We therefore conclude that the increased calcium release from ryanodine-sensitive calcium stores by BNP maybe responsible for the BNP-caused GABA(A) response suppression in ON-type BCs through stimulating calmodulin.

5-Nitro-2-(3-Phenylpropylamino)benzoic Acid Is a GPR35 Agonist

A Cell Permeable NPE Caged ADP-Ribose for Studying TRPM2

SAR Studies of N-[2-(1H-Tetrazol-5-yl)phenyl]benzamide Derivatives As Potent G Protein-Coupled Receptor-35 Agonists.

Study on Purpurin As A G Protein-coupled Receptor-35 Agonist

Recent advances in GPR35 pharmacology; 5-HIAA serotonin metabolite becomes a ligand

Human Neuropeptide S Receptor Is Activated via a Gαq Protein-biased Signaling Cascade by a Human Neuropeptide S Analog Lacking the C-terminal 10 Residues

Discovery of 2H-Chromen-2-one Derivatives As G Protein-Coupled Receptor-35 Agonists

Discovery of 3-((4-benzylpyridin-2-yl)amino)benzamide Derivatives as Potent GPR52 G Protein-Biased Agonists.

Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.

The Discovery of Potent Antagonists of NPBWR1 (GPR7).

Identifying the Localization and Exploring a Functional Role for Gprc5c in the Kidney.

Modulation of the G-Protein-Coupled Receptor 84 (GPR84) by Agonists and Antagonists

Structure-Activity Relationship Studies of Coumarin-like Diacid Derivatives As Human G Protein-Coupled Receptor-35 (hgpr35) Agonists and a Consequent New Design Principle.

Modulation by Brain Natriuretic Peptide of Gaba Receptors on Rat Retinal On-Type Bipolar Cells

Discovery and Characterization of Novel Antagonists of the Proinflammatory Orphan Receptor GPR84

Discovery and pharmacological effects of a novel GPR142 antagonist

Development and Characterization of Fluorescent Probes for the G Protein-Coupled Receptor 35.

Discovery of a novel GPR35 agonist with high and equipotent species potency for oral treatment of IBD

Phosphodiesters as GPR84 Antagonists for the Treatment of Ulcerative Colitis

A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies

Mitochondrial remodeling and ischemic protection by G protein–coupled receptor 35 agonists